Market Cap 77.82M
Revenue (ttm) 35.58M
Net Income (ttm) -17.89M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -50.28%
Debt to Equity Ratio 0.00
Volume 113,179
Avg Vol 66,594
Day's Range N/A - N/A
Shares Out 17.18M
Stochastic %K 13%
Beta 1.49
Analysts Strong Sell
Price Target $13.83

Company Profile

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that...

Industry: Biotechnology
Sector: Healthcare
Phone: 484 453 3300
Address:
44 West Gay Street, Suite 400, West Chester, United States
11thestate
11thestate Sep. 18 at 12:50 PM
When we see a stock like this, we know how many damaged investors are out there. Believe it or not, there’s some good news. $VRCA investors, you might be surprised, but you actually have a chance to recover your losses. Don’t miss it: https://11th.com/cases/verricapharmaceuticals-investor-settlement
0 · Reply
11thestate
11thestate Sep. 7 at 4:41 PM
Everything you need to know about the Verrica Pharmaceuticals ($VRCA) Settlement Payout Q: What happened? A: Verrica was accused of misleading investors about FDA inspection problems at Sterling, a key manufacturer for its VP-102 treatment, and the resulting risks to FDA approval. After the FDA issued multiple complete response letters tied to Sterling’s deficiencies, investors filed a lawsuit. Q: Am I actually eligible? A: If you bought or acquired $VRCA shares between 2021 and 2022, you may be eligible. You don’t need to still hold the stock to participate; past losses may qualify. Q: When do payouts happen? A: Typically, within 4–9 months after the claim deadline. But the exact timing depends on the court and settlement administration. Check if you're eligible and file a claim: https://11th.com/cases/verricapharmaceuticals-investor-settlement
0 · Reply
Leodus
Leodus Sep. 4 at 4:47 PM
$VRCA shaky can’t shank when he’s being shanked by the day of shorts
0 · Reply
AC_TRADER
AC_TRADER Aug. 30 at 8:05 AM
$VRCA levels mapped with @TrendSpider. https://share.trendspider.com/chart/VRCA/7594fiw5z4
0 · Reply
topstockalerts
topstockalerts Aug. 29 at 1:57 AM
$VRCA not much pullback at all… that’s interesting
0 · Reply
TheGodsMustBeCrazy
TheGodsMustBeCrazy Aug. 28 at 9:37 PM
$VRCA Can someone please explain to me the meaning of the interim analysis news from yesterday's VRCA press release?
1 · Reply
SnoopDawg
SnoopDawg Aug. 28 at 12:56 PM
$VRCA lake street initiates w a buy and target $9.
0 · Reply
TheGodsMustBeCrazy
TheGodsMustBeCrazy Aug. 28 at 12:49 AM
$VRCA today's interim analysis news
0 · Reply
prismmarketview
prismmarketview Aug. 27 at 5:31 PM
$VRCA — enrollment complete in COVE-2, the first of two pivotal Phase 3 trials for YCANTH in common warts. Blinded interim analysis says the trial is properly powered as-is. Topline data: Q1 2027. COVE-3 (US + Japan) already past 50% enrollment, running ahead of pace. Reminder: this is an operational milestone, not efficacy data — YCANTH is currently FDA-approved only for molluscum contagiosum. The real catalyst is still ~5 months out. https://prismmarketview.com/verrica-completes-pivotal-ycanth-phase-3-enrollment-for-common-warts-treatment/
0 · Reply
Merlintrader
Merlintrader Aug. 27 at 1:42 PM
$VRCA Verrica Pharmaceuticals stock hub: COVE-2 fully enrolled with topline data guided to Q1 2027, against a going-concern statement filed three weeks earlier. Free to read, no subscription. https://www.merlintrader.com/verrica-vrca-stock-hub/?utm_source=stocktwits&utm_medium=social&utm_campaign=verrica-vrca-stock-hub
0 · Reply
Latest News on VRCA
Verrica Pharmaceuticals Slides: Corporate presentation

Sep 14, 2026, 7:00 AM EDT - 4 days ago

Verrica Pharmaceuticals Slides: Corporate presentation


Lake Street starts Verrica Pharmaceuticals with a Buy

2026-08-27T12:45:49.000Z - 22 days ago

Lake Street starts Verrica Pharmaceuticals with a Buy


Verrica Pharmaceuticals initiated with a Buy at Lake Street

2026-08-27T12:00:49.000Z - 22 days ago

Verrica Pharmaceuticals initiated with a Buy at Lake Street


Verrica Pharmaceuticals CEO buys $125.8K in common stock

2026-08-18T21:10:11.000Z - 4 weeks ago

Verrica Pharmaceuticals CEO buys $125.8K in common stock


Verrica Pharmaceuticals reports Q2 EPS (62c), consensus (47c)

2026-08-06T21:31:11.000Z - 6 weeks ago

Verrica Pharmaceuticals reports Q2 EPS (62c), consensus (47c)


Verrica Pharmaceuticals Earnings Call Transcript: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 6 weeks ago

Verrica Pharmaceuticals Earnings Call Transcript: Q2 2026


Verrica Pharmaceuticals Earnings release: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 6 weeks ago

Verrica Pharmaceuticals Earnings release: Q2 2026


Verrica Pharmaceuticals Quarterly report: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 6 weeks ago

Verrica Pharmaceuticals Quarterly report: Q2 2026


Verrica Pharmaceuticals Slides: Corporate presentation

Aug 1, 2026, 8:00 AM EDT - 6 weeks ago

Verrica Pharmaceuticals Slides: Corporate presentation


Verrica Pharmaceuticals assumed with a Buy at H.C. Wainwright

2026-05-26T10:19:56.000Z - 3 months ago

Verrica Pharmaceuticals assumed with a Buy at H.C. Wainwright


Verrica Pharmaceuticals Earnings Call Transcript: Q1 2026

May 12, 2026, 4:30 PM EDT - 4 months ago

Verrica Pharmaceuticals Earnings Call Transcript: Q1 2026


Verrica Pharmaceuticals Earnings release: Q1 2026

May 12, 2026, 4:30 PM EDT - 4 months ago

Verrica Pharmaceuticals Earnings release: Q1 2026


Verrica Pharmaceuticals Quarterly report: Q1 2026

May 12, 2026, 4:30 PM EDT - 4 months ago

Verrica Pharmaceuticals Quarterly report: Q1 2026


Verrica Pharmaceuticals Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 5 months ago

Verrica Pharmaceuticals Proxy statement: Proxy filing


Verrica Pharmaceuticals Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 5 months ago

Verrica Pharmaceuticals Proxy statement: Proxy filing


Verrica Pharmaceuticals Slides: Corporate presentation

Mar 27, 2026, 8:00 AM EDT - 5 months ago

Verrica Pharmaceuticals Slides: Corporate presentation


Verrica Pharmaceuticals Earnings Call Transcript: Q4 2025

Mar 11, 2026, 8:30 AM EDT - 6 months ago

Verrica Pharmaceuticals Earnings Call Transcript: Q4 2025


Verrica Pharmaceuticals Annual report: Q4 2025

Mar 11, 2026, 8:30 AM EDT - 6 months ago

Verrica Pharmaceuticals Annual report: Q4 2025


Verrica Pharmaceuticals Earnings release: Q4 2025

Mar 11, 2026, 8:30 AM EDT - 6 months ago

Verrica Pharmaceuticals Earnings release: Q4 2025


Verrica Pharmaceuticals Slides: Investor presentation

Jan 9, 2026, 7:00 AM EST - 8 months ago

Verrica Pharmaceuticals Slides: Investor presentation


Verrica Pharmaceuticals upgraded to Buy from Hold at Brookline

2025-12-18T02:10:17.000Z - 9 months ago

Verrica Pharmaceuticals upgraded to Buy from Hold at Brookline


Verrica Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 17, 2025, 8:30 AM EST - 10 months ago

Verrica Pharmaceuticals Earnings Call Transcript: Q3 2025


Verrica Pharmaceuticals Earnings release: Q3 2025

Nov 17, 2025, 8:30 AM EST - 10 months ago

Verrica Pharmaceuticals Earnings release: Q3 2025


Verrica Pharmaceuticals Quarterly report: Q3 2025

Nov 17, 2025, 8:30 AM EST - 10 months ago

Verrica Pharmaceuticals Quarterly report: Q3 2025


Verrica Pharmaceuticals initiated with a Buy at Lucid Capital

2025-11-05T11:46:01.000Z - 10 months ago

Verrica Pharmaceuticals initiated with a Buy at Lucid Capital


Verrica Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 1 year ago

Verrica Pharmaceuticals Earnings Call Transcript: Q2 2025


Verrica Pharmaceuticals Quarterly report: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 1 year ago

Verrica Pharmaceuticals Quarterly report: Q2 2025


Verrica Pharmaceuticals Earnings release: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 1 year ago

Verrica Pharmaceuticals Earnings release: Q2 2025


Verrica Pharmaceuticals Earnings Call Transcript: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Verrica Pharmaceuticals Earnings Call Transcript: Q1 2025


Verrica Pharmaceuticals Quarterly report: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Verrica Pharmaceuticals Quarterly report: Q1 2025


Verrica Pharmaceuticals Earnings release: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Verrica Pharmaceuticals Earnings release: Q1 2025


Verrica Pharmaceuticals Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Verrica Pharmaceuticals Proxy statement: Proxy Filing


Verrica Pharmaceuticals Proxy statement: Proxy Filing

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Verrica Pharmaceuticals Proxy statement: Proxy Filing


Verrica Pharmaceuticals Proxy statement: Proxy Filing

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Verrica Pharmaceuticals Proxy statement: Proxy Filing


Verrica Pharmaceuticals Proxy statement: Proxy Filing

Apr 11, 2025, 8:00 AM EDT - 1 year ago

Verrica Pharmaceuticals Proxy statement: Proxy Filing


Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D.

Mar 26, 2025, 7:00 AM EDT - 1 year ago

Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D.


Verrica Pharmaceuticals Earnings Call Transcript: Q4 2024

Mar 11, 2025, 4:30 PM EDT - 1 year ago

Verrica Pharmaceuticals Earnings Call Transcript: Q4 2024


Verrica Pharmaceuticals Annual report: Q4 2024

Mar 11, 2025, 4:30 PM EDT - 1 year ago

Verrica Pharmaceuticals Annual report: Q4 2024


Verrica Pharmaceuticals Earnings release: Q4 2024

Mar 11, 2025, 4:30 PM EDT - 1 year ago

Verrica Pharmaceuticals Earnings release: Q4 2024


Verrica Announces Pricing of $42.0 Million Public Offering

Nov 21, 2024, 7:30 AM EST - 1 year ago

Verrica Announces Pricing of $42.0 Million Public Offering


Verrica Announces Proposed Public Offering

Nov 20, 2024, 4:05 PM EST - 1 year ago

Verrica Announces Proposed Public Offering


Verrica Pharmaceuticals Quarterly report: Q3 2024

Nov 4, 2024, 9:30 AM EST - 1 year ago

Verrica Pharmaceuticals Quarterly report: Q3 2024


Verrica Pharmaceuticals Earnings release: Q3 2024

Nov 4, 2024, 9:30 AM EST - 1 year ago

Verrica Pharmaceuticals Earnings release: Q3 2024


11thestate
11thestate Sep. 18 at 12:50 PM
When we see a stock like this, we know how many damaged investors are out there. Believe it or not, there’s some good news. $VRCA investors, you might be surprised, but you actually have a chance to recover your losses. Don’t miss it: https://11th.com/cases/verricapharmaceuticals-investor-settlement
0 · Reply
11thestate
11thestate Sep. 7 at 4:41 PM
Everything you need to know about the Verrica Pharmaceuticals ($VRCA) Settlement Payout Q: What happened? A: Verrica was accused of misleading investors about FDA inspection problems at Sterling, a key manufacturer for its VP-102 treatment, and the resulting risks to FDA approval. After the FDA issued multiple complete response letters tied to Sterling’s deficiencies, investors filed a lawsuit. Q: Am I actually eligible? A: If you bought or acquired $VRCA shares between 2021 and 2022, you may be eligible. You don’t need to still hold the stock to participate; past losses may qualify. Q: When do payouts happen? A: Typically, within 4–9 months after the claim deadline. But the exact timing depends on the court and settlement administration. Check if you're eligible and file a claim: https://11th.com/cases/verricapharmaceuticals-investor-settlement
0 · Reply
Leodus
Leodus Sep. 4 at 4:47 PM
$VRCA shaky can’t shank when he’s being shanked by the day of shorts
0 · Reply
AC_TRADER
AC_TRADER Aug. 30 at 8:05 AM
$VRCA levels mapped with @TrendSpider. https://share.trendspider.com/chart/VRCA/7594fiw5z4
0 · Reply
topstockalerts
topstockalerts Aug. 29 at 1:57 AM
$VRCA not much pullback at all… that’s interesting
0 · Reply
TheGodsMustBeCrazy
TheGodsMustBeCrazy Aug. 28 at 9:37 PM
$VRCA Can someone please explain to me the meaning of the interim analysis news from yesterday's VRCA press release?
1 · Reply
SnoopDawg
SnoopDawg Aug. 28 at 12:56 PM
$VRCA lake street initiates w a buy and target $9.
0 · Reply
TheGodsMustBeCrazy
TheGodsMustBeCrazy Aug. 28 at 12:49 AM
$VRCA today's interim analysis news
0 · Reply
prismmarketview
prismmarketview Aug. 27 at 5:31 PM
$VRCA — enrollment complete in COVE-2, the first of two pivotal Phase 3 trials for YCANTH in common warts. Blinded interim analysis says the trial is properly powered as-is. Topline data: Q1 2027. COVE-3 (US + Japan) already past 50% enrollment, running ahead of pace. Reminder: this is an operational milestone, not efficacy data — YCANTH is currently FDA-approved only for molluscum contagiosum. The real catalyst is still ~5 months out. https://prismmarketview.com/verrica-completes-pivotal-ycanth-phase-3-enrollment-for-common-warts-treatment/
0 · Reply
Merlintrader
Merlintrader Aug. 27 at 1:42 PM
$VRCA Verrica Pharmaceuticals stock hub: COVE-2 fully enrolled with topline data guided to Q1 2027, against a going-concern statement filed three weeks earlier. Free to read, no subscription. https://www.merlintrader.com/verrica-vrca-stock-hub/?utm_source=stocktwits&utm_medium=social&utm_campaign=verrica-vrca-stock-hub
0 · Reply
11thestate
11thestate Aug. 21 at 12:36 PM
Verrica Pharmaceuticals Agreed to Settle With Investors over FDA Approval Risk Claims The $VRCA settlement centered on claims that Verrica misled investors about FDA inspection problems at Sterling, a key manufacturer of its VP-102 treatment, and the resulting approval risks. In 2022, Verrica disclosed a third FDA complete response letter after another inspection found problems at Sterling. Investors filed a lawsuit. So if you purchased $VRCA between 2021 and 2022, you may be eligible to participate once claims filing opens: https://11th.com/cases/verricapharmaceuticals-investor-settlement
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Aug. 18 at 11:05 PM
$VRCA CEO purchased 25,000 shares at $5.03 for a total of $125,750. Rieger Jayson now owns 207,838 shares. https://ceo-buys.com
0 · Reply
DonCorleone77
DonCorleone77 Aug. 18 at 9:38 PM
$VRCA Verrica Pharmaceuticals CEO buys $125.8K in common stock In a regulatory filing, Verrica Pharmaceuticals disclosed that its CEO Jayson Rieger bought 25K shares of common stock on August 14th in a total transaction size of $125.8K.
0 · Reply
JFais
JFais Aug. 18 at 9:29 PM
$VRCA (NP) Former Black Sheep pick, CEO with $125.8K purchase 🧐
0 · Reply
BDE_Worldwide
BDE_Worldwide Aug. 6 at 10:51 PM
$VRCA been here a looooong time.. surprised to see PBM still shoveling money into this enterprise.. wonder what he sees..?
1 · Reply
BioGem
BioGem Aug. 6 at 10:42 PM
$VRCA The same exact points I mentioned before, persist and worsen over time. Most importantly, adoption by doctors is too poor, and cash ran out, while losses are destroying the company. Now they are adding expensive debt.
1 · Reply
AlphaMatrix
AlphaMatrix Aug. 6 at 10:31 PM
$VRCA units surged but revenue barely moved. Monetization gap is widening. Physicians adopting. Patients not paying.
0 · Reply
EarningsInsider
EarningsInsider Aug. 6 at 9:32 PM
https://www.marketbeat.com/earnings/reports/2026-8-6-verrica-pharmaceuticals-inc-stock/ $VRCA Verrica Pharmaceuticals Earnings Transcript
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Aug. 6 at 8:44 PM
$VRCA Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.62 down -3200.00% YoY • Reported revenue of $5.86M down -53.85% YoY
0 · Reply
11thestate
11thestate Aug. 5 at 7:39 PM
Verrica Pharmaceuticals ($VRCA) finally agreed to settle with investors over claims it misled the market about FDA approval risks for VP-102. What happened? Investors alleged Verrica downplayed manufacturing problems at Sterling, a key contract manufacturer for VP-102, and repeatedly suggested FDA issues had been resolved. In May 2022, the company disclosed a third Complete Response Letter tied to Sterling, raising new concerns about the drug's approval timeline. Who qualifies? Investors who purchased $VRCA between 2021 and 2022. Apply here: https://11th.com/cases/verricapharmaceuticals-investor-settlement
0 · Reply
Stock_Catcher
Stock_Catcher Jul. 21 at 12:03 PM
$VRCA Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel
0 · Reply
Bbboston
Bbboston Jul. 20 at 7:33 PM
$VRCA Yahoo showing Only 4950 shares traded today so far and it’s 3:30!!!
0 · Reply